<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.112116</article-id><article-id pub-id-type="publisher-id">ACM-40751</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210200000_48996109.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  血管内皮生长因子(VEGF)与神经系统疾病相关性研究进展
  Research Progress on the Relationship between Vascular Endothelial Growth Factor (VEGF) and Nervous System Diseases
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>晓扬</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>吕</surname><given-names>婷</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>光路</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>内蒙古医科大学，内蒙古 呼和浩特</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>05</day><month>02</month><year>2021</year></pub-date><volume>11</volume><issue>02</issue><fpage>821</fpage><lpage>825</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    血管内皮生长因子(vascular endothelial growth factor, VEGF)是一种具有高特异性重要促血管生成活性的生长因子，具有促进血管内皮细胞增殖分化，促进血管发生、血管生成、促进细胞迁移、抑制肿瘤细胞凋亡等作用，在调节正常和病理性血管生成过程中发挥积极作用，本文总结了神经系统多种疾病如癫痫、惊厥、脑梗死、脑肿瘤、脊髓炎及注意力缺陷多动障碍等与VEGF表达的相关性进展，目前，利用抗VEGF和抗VEGFRs治疗来阻断肿瘤或其他病理过程中的血管生成被认为是极其重要的。
    Vascular endothelial growth factor (VEGF) is a kind of growth factor with high specific and important angiogenic activity. It can promote the proliferation and differentiation of vascular endothelial cells, promote angiogenesis, promote cell migration, inhibit tumor cell apoptosis, and play an active role in the regulation of normal and pathological angiogenesis. This paper summarized the progress of the correlation between the expression of VEGF and various diseases of nervous system, such as epilepsy, convulsion, cerebral infarction, brain tumor, myelitis and attention deficit hyperactivity disorder. At present, the use of anti VEGF and anti VEGFRs therapy to block angiogenesis in tumor or other pathological processes is considered to be extremely important. 
  
 
</p></abstract><kwd-group><kwd>VEGF，癫痫，脑卒中，视神经脊髓炎, VEGF</kwd><kwd> Epilepsy</kwd><kwd> Cerebral Apoplexy</kwd><kwd> Neuromyelitis Optica</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>血管内皮生长因子(vascular endothelial growth factor, VEGF)是一种具有高特异性重要促血管生成活性的生长因子，具有促进血管内皮细胞增殖分化，促进血管发生、血管生成、促进细胞迁移、抑制肿瘤细胞凋亡等作用，在调节正常和病理性血管生成过程中发挥积极作用，本文总结了神经系统多种疾病如癫痫、惊厥、脑梗死、脑肿瘤、脊髓炎及注意力缺陷多动障碍等与VEGF表达的相关性进展，目前，利用抗VEGF和抗VEGFRs治疗来阻断肿瘤或其他病理过程中的血管生成被认为是极其重要的。</p></sec><sec id="s2"><title>关键词</title><p>VEGF，癫痫，脑卒中，视神经脊髓炎</p></sec><sec id="s3"><title>Research Progress on the Relationship between Vascular Endothelial Growth Factor (VEGF) and Nervous System Diseases<sup> </sup></title><p>Xiaoyang Liu, Ting Lv, Guanglu Yang<sup>*</sup></p><p>Inner Mongolia Medical University, Hohhot Inner Mongolia</p><p><img src="//html.hanspub.org/file/55-1571965x4_hanspub.png" /></p><p>Received: Jan. 25<sup>th</sup>, 2021; accepted: Feb. 9<sup>th</sup>, 2021; published: Feb. 26<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/55-1571965x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Vascular endothelial growth factor (VEGF) is a kind of growth factor with high specific and important angiogenic activity. It can promote the proliferation and differentiation of vascular endothelial cells, promote angiogenesis, promote cell migration, inhibit tumor cell apoptosis, and play an active role in the regulation of normal and pathological angiogenesis. This paper summarized the progress of the correlation between the expression of VEGF and various diseases of nervous system, such as epilepsy, convulsion, cerebral infarction, brain tumor, myelitis and attention deficit hyperactivity disorder. At present, the use of anti VEGF and anti VEGFRs therapy to block angiogenesis in tumor or other pathological processes is considered to be extremely important.</p><p>Keywords:VEGF, Epilepsy, Cerebral Apoplexy, Neuromyelitis Optica</p><disp-formula id="hanspub.40751-formula82"><graphic xlink:href="//html.hanspub.org/file/55-1571965x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/55-1571965x8_hanspub.png" /> <img src="//html.hanspub.org/file/55-1571965x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 血管内皮生长因子(Vascular Endothelial Growth Factor, VEGF)概述</title><p>血管内皮生长因子(VEGF)是一种具有高特异性重要促血管生成活性的生长因子，具有促进血管内皮细胞增殖分化，促进血管发生、血管生成、增强血管渗透性、促进细胞迁移、抑制肿瘤细胞凋亡等作用，在调节正常和病理性血管生成过程中发挥积极作用 [<xref ref-type="bibr" rid="hanspub.40751-ref1">1</xref>]，人血管内皮生长因子基因位于6p21.3染色体上，是血管内皮生长因子/血小板衍生生长因子(PDGF)基因家族的一部分。从结构上看，VEGF是一种40 kDa的异二聚体糖蛋白，含有半胱氨酸结基序，其特征是蛋白结构中存在一定的二硫键 [<xref ref-type="bibr" rid="hanspub.40751-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.40751-ref3">3</xref>]。在人类中，VEGF家族由几个成员组成：VEGF-A (有不同的异构体)、VEGF-B、VEGF-C、VEGF-D、VEGF-E (病毒VEGF)、VEGF-F (蛇毒VEGF)、胎盘生长因子(PlGF)，最近又增加了内分泌腺源性血管内皮生长因子(EG-VEGF)；其中VEGF-C、VEGF-D具有促进淋巴管生成的作用，在肿瘤的淋巴转移中起着重要作用。VEGF通过与血管内皮细胞上的酪氨酸激酶细胞受体(VEGFRs)结合而发挥作用，VEGFRs主要分为：VEGFR-1 (Flt-1)、VEGFR-2 [(KDR), (Flk-1)]和VEGFR-3 (Flt-4)。VEGFR-1和VEGFR-2主要表达于血管内皮细胞，而VEGFR-3主要表达于淋巴管内皮细胞。VEGFR-1在内皮细胞、单核细胞、巨噬细胞和造血干细胞的迁移中发挥重要作用，因此主要参与成人生活中的病理性血管生成(肿瘤、炎症、缺血等)。VEGFR-1对VEGF的亲和力是VEGFR-2的10倍，而酪氨酸激酶活性较低，在不同条件下，它对于血管生成的调控具有促进或抑制的双重作用，病理情况下VEGFR1可通过其酪氨酸激酶活性区域正性调节血管生成，VEGFR-1只参与内皮细胞的分化，而不积极参与胚胎发育过程中血管生成的早期阶段；与VEGFR-1相比，VEGFR-2具有更强的促血管生成活性和更高的酪氨酸激酶活性，是VEGF/VEGFR信号传导途径中主要信号传递体，在血管形成过程中起重要调控作用。VEGF和VEGFRs不仅在内皮细胞上表达，在非内皮细胞上也有表达 [<xref ref-type="bibr" rid="hanspub.40751-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.40751-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.40751-ref5">5</xref>]。目前，利用抗VEGF和抗VEGFRs治疗来阻断肿瘤或其他病理过程中的血管生成被认为是极其重要的。</p></sec><sec id="s6"><title>2. VEGF与癫痫</title><p>癫痫(Epilepsy, EP)是以自发、反复抽搐发作为特点的严重神经系统疾病，其发病机制为大脑神经元高度同步化异常放电，会对患儿相应的神经生理、认知、心理及社会等方面造成损害，是儿童最常见的神经系统疾病 [<xref ref-type="bibr" rid="hanspub.40751-ref6">6</xref>]。癫痫持续状态(Status epilepticus, SE)指一次发作持续30分钟以上，或连续反复发作30分钟以上，发作间歇期意识不恢复者 [<xref ref-type="bibr" rid="hanspub.40751-ref7">7</xref>]；SE是癫痫患者最严重的癫痫发作形式，发育期SE可造成明显的脑损伤及远期神经行为异常；SE可导致海马CA3区明显的细胞死亡且该区胞质中Bax蛋白表达急剧增加，而Bcl-2的蛋白表达却明显降低，海马神经元凋亡既是癫痫发作的结果，也是潜伏期中环路重建导致惊厥反复发作的重要原因，因此海马神经元的凋亡在癫痫的发病中起主导作用，VEGF作为一种促血管生成因子，同时具有神经保护作用，其可以直接作用于神经元与神经胶质细胞，促进神经元的增殖、存活、突触生长，刺激施万细胞延伸、增殖、并可分化出星形胶质细胞和小胶质细胞，促进损伤的神经组织再生和修复，是一种独立的神经保护因子，其神经保护作用主要体现在以下方面：① 促进血管再生；② 直接的神经保护作用：抗细胞凋亡、降低氧化应激、调节离子通道、抑制突触传递；③ 促进神经元再生和轴突形成 [<xref ref-type="bibr" rid="hanspub.40751-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.40751-ref8">8</xref>]，研究发现VEGF通过诱导Bcl-2和抑制Bax蛋白表达来发挥发育期SE后急性期与远期海马凋亡损伤的神经保护作用，尤以0.04 μg VEGF组效果最好，VEGF减少神经细胞凋亡的机制主要是VEGF与VEGF受体结合后激活PI3K/Akt (磷脂酰肌醇3激酶/丝氨酸激酶) [<xref ref-type="bibr" rid="hanspub.40751-ref9">9</xref>]，一方面抑制促凋亡蛋白进而抑制半胱氨酸蛋白caspase-9及其下游效应因子，避免细胞发生凋亡；另一方面使凋亡抑制蛋白表达增加，从而抑制caspase-3、7、9介导的细胞凋亡，此外在脑组织缺血缺氧条件下，VEGF可诱导低氧诱导因子(Hypoxia inducible factor, HIF)的产生，HIF可以与低氧诱导因子受体(Hypoxia inducible factor receptor, HRE)结合上调VEGF的表达，从而调节Bax及Bcl-2的表达，从而发挥神经保护作用 [<xref ref-type="bibr" rid="hanspub.40751-ref10">10</xref>]，在未成熟脑惊厥持续状态(SC)时，VEGF可促进急性期海马神经干细胞增殖，减少SC所致的海马CA1区和CA3区神经元丢失，改善未成熟脑SC后海马的病理损伤，对神经元有直接的保护作用 [<xref ref-type="bibr" rid="hanspub.40751-ref11">11</xref>]。</p></sec><sec id="s7"><title>3. VEGF与脑卒中</title><p>脑卒中是由于动脉严重狭窄或闭塞导致脑组织缺血缺氧的一种临床常见脑血管疾病，Willis环交通支开放供血，颅外动脉系统通过颞浅动脉–眼动脉血管连接，颅内动脉系统通过软脑膜与脑膜动脉血管连接，或不同脑室间软脑膜血管相互连接形成，即为侧支循环形成，侧支循环级数越高，提示侧支循环形成越良好，良好的侧支循环可减少脑缺血发生率且预示预后良好，且可能有利于减轻神经缺损程度 [<xref ref-type="bibr" rid="hanspub.40751-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.40751-ref13">13</xref>]。研究表明VEGF血清水平与脑梗死灶大小及神经功能缺损评分明显相关。VEGF主要通过诱导内皮细胞增殖和体内新生血管形成改善缺血性脑卒中患者预后，同时也可通过下调凋亡基因半胱天冬酶(caspase)-3，-9，-12及c-jun的表达，抑制反应性凋亡途径的激活发挥其神经保护作用。CLIC４通常在内皮细胞和血管平滑肌细胞中表达，并且对于在胚胎发生和缺血期间血管形成是必需的，发生缺血性脑卒中后，CLIC4上调VEGF的表达，VEGF与其受体结合后通过MAPK信号通路，将信号传递至细胞核内激活DNA的合成，同时动员Ca<sup>2+</sup>信使以及双孔通道TPC2亚型对酸性细胞内Ca<sup>2+</sup>储存物的特异性接合，导致Ca<sup>2+</sup>释放，促进内皮细胞的增殖及血管生成反应，从而促进侧支循环的形成，有助于恢复半暗带甚至是缺血中心的血流 [<xref ref-type="bibr" rid="hanspub.40751-ref14">14</xref>]，检测血清VEGF水平可辅助判断缺血性脑卒中患者病情和预后。</p></sec><sec id="s8"><title>4. VEGF与视神经脊髓炎</title><p>视神经脊髓炎(neuromyelitis optica, NMO)和(或)视神经脊髓炎谱系疾病(neuromyelitis optica spectrum disease, NMOSD)是一种特发性炎性脱髓鞘疾病，病变主要侵犯视神经和脊髓，导致严重的视神经炎和横贯性脊髓炎 [<xref ref-type="bibr" rid="hanspub.40751-ref15">15</xref>]。NMOSD是一种涉及多种细胞参与的复杂免疫病理过程，而细胞因子/趋化因子是细胞间的生物活性多肽信使，通过对于不同细胞的多效性作用导致免疫系统激活，包括免疫细胞的增殖、分化及聚集从而导致炎性反应的发生、致病。血清AQPIgG在诊断NMO/NMOSD上有较高的敏感性和特异性，VEGF是一种新血管生成的诱导因子，可介导血管的多项生理功能，尤其是可刺激血管平滑肌细胞增生和分化，也是目前诱导新血管生成最强的物质，VEGF-A是一种血脑屏障(blood-brain barrier, BBB)破坏的生物标记物，其在脱髓鞘病变中参与促进BBB的破坏，但应用VEGF-A拮抗剂后可以阻止上述过程的发生，表明VEGF-A在NMO的发病过程中可能发挥着潜在的作用，NMOSD为一种炎性脱髓鞘疾病，只有在血–脑屏障破坏的前提下，AQP-4抗体才具有致病性，血脑屏障破坏在NMOSD的发病中起着重要作用。而VEGF-A是血脑屏障破坏的生物标记物，且体外实验中已证实VEGF-A在NMO的发病过程中存在一定作用 [<xref ref-type="bibr" rid="hanspub.40751-ref16">16</xref>]，NMO在发病过程中可能由于其星形胶质细胞产生的损伤较髓鞘脱失严重，机体免疫反应强烈，加之星形胶质细胞是抗原呈递细胞，其在被激活或损伤之后能够分泌出更多的多类细胞因子，刺激和促使VEGF、BAFF等因子表达上升，导致B细胞形成的AQP4-Ab上调，最终促发NMO的发生。EDSS评分则是临床上评估NMO病情的量表，可有效反映患者视神经功能损害情况，Pearson相关性分析显示，脑脊液BAFF、VEGF水平均与EDSS评分呈正相关(r = 0.695, P &lt; 0.001; r = 0.668, P &lt; 0.001)，提示检测其水平可作为评估NMO病情的重要参考指标，且临床上应进行联合检测 [<xref ref-type="bibr" rid="hanspub.40751-ref17">17</xref>]。</p></sec><sec id="s9"><title>5. VEGF与其他神经系统疾病</title><p>VEGF目前被认为是脑部损伤中发挥重要作用的细胞因子，其释放增加可引起血脑屏障通透性的增加，因此具有很强的扰乱和损伤血脑屏障的作用，VEGF最受关注的生理功能是参与肿瘤生长、转移及炎症反应过程，除此之外，它还能在较低浓度时就表现出较强的增加血管通透性的作用且效应是组胺作用浓度的5万倍，因此VEGF释放增加可引起血脑屏障通透性增加导致脑水肿形成，在颅内感染早期病毒引发宿主的炎症反应炎症细胞和血小板等均可生成VEGF与病毒性脑炎的发生发展有密切关系 [<xref ref-type="bibr" rid="hanspub.40751-ref18">18</xref>]；VEGF在注意力缺陷多动障碍(Attention deficit hyperactivity disorder, ADHD)患儿血清中的水平是下降的，提示提示VEGF可能参与ADHD的发病机制 [<xref ref-type="bibr" rid="hanspub.40751-ref19">19</xref>]，VEGF表达的刺激促进神经传递和突触可塑性过程，如神经发生，这些血管内皮生长因子在大脑中的作用，可能是其对精神病和其他神经疾病有益的治疗作用的基础，如阿尔兹海默病等 [<xref ref-type="bibr" rid="hanspub.40751-ref20">20</xref>]。</p></sec><sec id="s10"><title>6. 展望</title><p>目前已有一些以VEGF/VEGFR为靶点治疗药物用于临床抗肿瘤治疗，如贝伐单抗、VEGF-Trap等，并且被认为可用于治疗多种与血管生成密切相关的疾病 [<xref ref-type="bibr" rid="hanspub.40751-ref18">18</xref>]，VEGF参与多种中枢神经系统疾病发病机制，但关于其作用机制还不明朗，通过深入研究，或许我们可以获得靶向药物，实现精准医疗，从而造福广大患者。</p></sec><sec id="s11"><title>文章引用</title><p>刘晓扬,吕 婷,杨光路. 血管内皮生长因子(VEGF)与神经系统疾病相关性研究进展Research Progress on the Relationship between Vascular Endothelial Growth Factor (VEGF) and Nervous System Diseases[J]. 临床医学进展, 2021, 11(02): 821-825. https://doi.org/10.12677/ACM.2021.112116</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40751-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Melincovici, C.S., Boşca, A.B., Şuşman, S., Mărginean, M., Mihu, C., Istrate, M., Moldovan, I.M., Roman, A.L. and Mihu, C.M. (2018) Vascular Endothelial Growth Factor (VEGF)—Key Factor in Normal and Pathological Angiogenesis. Romanian Journal of Morphology and Embryology, 59, 455-467.</mixed-citation></ref><ref id="hanspub.40751-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Yamazaki, Y. and Morita, T. (2006) Molecular and Functional Diversity of Vascular Endothelial Growth Factors. Molecular Diversity, 10, 515-527. https://doi.org/10.1007/s11030-006-9027-3</mixed-citation></ref><ref id="hanspub.40751-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Takahashi, H. and Shibuya, M. (2005) The Vascular Endothelial Growth Factor (VEGF)/VEGF Receptor System and Its Role under Physiological and Pathological Conditions. Clinical Science (London), 109, 227-241.  
https://doi.org/10.1042/CS20040370</mixed-citation></ref><ref id="hanspub.40751-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Olsson, A.K., Dimberg, A., Kreuger, J. and Claesson-Welsh, L. (2006) VEGF Receptor Signaling—In Control of Vascular Function. Nature Reviews Molecular Cell Biology, 7, 359-371. https://doi.org/10.1038/nrm1911</mixed-citation></ref><ref id="hanspub.40751-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">张菡菡, 孔丽君, 胡金霞, 等. 靶向VEGF/VEGFR的RNA干扰与肿瘤关系的探讨[J]. 滨州医学院学报, 2012, 35(4): 316-318.</mixed-citation></ref><ref id="hanspub.40751-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Hui, Y.Y., Ahmad, N. and Makmor-Bakry, M. (2013) Pathogenesis of Epilepsy: Challenges in Animal Models. Iranian Journal of Basic Medical Sciences, 16, 1119-1132.</mixed-citation></ref><ref id="hanspub.40751-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">刘聪聪. 血管内皮生长因子对发育期癫痫持续状态的神经保护作用的研究[D]: [硕士学位论文]. 苏州: 苏州大学, 2016.</mixed-citation></ref><ref id="hanspub.40751-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Plow, E.F., Meller, J. and Byzova, T.V. (2014) Integrin Function in Vascular Biology: A View from 2013. Current Opinion in Hematology, 21, 241-247. https://doi.org/10.1097/MOH.0000000000000042</mixed-citation></ref><ref id="hanspub.40751-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Koch, S. and Claesson-Welsh, L. (2012) Signal Transduction by Vascular Endothelial Growth Factor Receptors. Cold Spring Harbor Perspectives in Medicine, 2, a006502. https://doi.org/10.1101/cshperspect.a006502</mixed-citation></ref><ref id="hanspub.40751-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Yao, X.H., Ping, Y.F., Liu, Y., et al. (2013) Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) Plays a Key Role in Vasculogenic Mimicry Formation, Neovascularization and Tumor Initiation by Glioma Stem-Like Cells. PLoS ONE, 8, e57188. https://doi.org/10.1371/journal.pone.0057188</mixed-citation></ref><ref id="hanspub.40751-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">韩慰. 时相性调控VEGF对未成熟脑惊厥持续状态后癫痫形成的影响[D]: [博士学位论文]. 重庆: 重庆医科大学, 2019.</mixed-citation></ref><ref id="hanspub.40751-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">张照楠, 宿伟鹏, 张洋, 等. 脑胶质瘤组织中微小RNA-21水平及其与EGFR和VEGF表达的关系[J]. 临床肿瘤学杂志, 2018, 23(6): 514-518.</mixed-citation></ref><ref id="hanspub.40751-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">van Kranendonk, K.R., Treurniet, K.M., Boers, A.M.M., et al. (2019) Hemorrhagic Transformation Is Associated with Poor Functional Outcome in Patients with Acute Ischemic Stroke Due to a Large Vessel Occlusion. Journal of NeuroInterventional Surgery, 11, 464-468. https://doi.org/10.1136/neurintsurg-2018-014141</mixed-citation></ref><ref id="hanspub.40751-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">方丽萍. VEGF促进缺血性脑梗死侧支循环形成的研究进展[J]. 癫痫与神经电生理学杂志, 2018, 27(3): 181-183, 189.</mixed-citation></ref><ref id="hanspub.40751-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Wingerchuk, D.M., Lennon, V.A., Lucchinetti, C.F., et al. (2007) The Spectrum of Neuromyelitis Optica. The Lancet Neurology, 6, 805-815. https://doi.org/10.1016/S1474-4422(07)70216-8</mixed-citation></ref><ref id="hanspub.40751-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">马秋英, 刘磊, 康雯婷, 等. 视神经脊髓炎谱系疾病患者血清生物标记物水平的研究[J]. 中国神经免疫学和神经病学杂志, 2019, 26(6): 420-426.</mixed-citation></ref><ref id="hanspub.40751-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">李再来. 脑脊液BAFF、VEGF水平在视神经脊髓炎患者中的变化及其意义[J]. 卒中与神经疾病, 2018, 25(6): 681-684.</mixed-citation></ref><ref id="hanspub.40751-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">成芳芳, 陈庆会, 李嫣, 等. VEGF基因多态性与手足口病脑炎易患性关系研究[J]. 国际儿科学杂志, 2020, 47(10): 746-748.</mixed-citation></ref><ref id="hanspub.40751-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Yurteri, N., Sahin, I.E. and Tufan, A.E. (2019) Altered Serum Levels of Vascular Endothelial Growth Factor and Glial-Derived Neurotrophic Factor But Not Fibroblast Growth Factor-2 in Treatment-Naive Children with Attention Deficit/Hyperactivity Disorder. Nordic Journal of Psychiatry, 73, 302-307.  
https://doi.org/10.1080/08039488.2019.1625437</mixed-citation></ref><ref id="hanspub.40751-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Echeverria, V., Barreto, G.E., Avila-Rodriguez, M., et al. (2017) Is VEGF a Key Target of Cotinine and Other Potential Therapies against Alzheimer Disease? Current Alzheimer Research, 14, 1155-1163.  
https://doi.org/10.2174/1567205014666170329113007</mixed-citation></ref></ref-list></back></article>